Sign Up
Stories
Autolus Thrives with $350M Offering and Strategic Collaborations
Share
BCMA-Targeted CAR-T Cell Therapy Progres...
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Cancer Drug Trials
Abeona Therapeutics Grants Inducement Aw...
Overview
API
Autolus Therapeutics secures $350 million through an underwritten offering, plans to expand its pipeline with BioNTech's investment, and enters a strategic collaboration with BioNTech to advance autologous CAR-T cell therapy.
Ask a question
How might the investment from BioNTech affect Autolus's position in the competitive biopharmaceutical market?
How might the underwritten offering impact Autolus Therapeutics' future research and development initiatives?
What potential benefits could the collaboration between Autolus and BioNTech bring to the field of cell therapies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Feb 2024
Coverage
marke
stree